These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30942559)

  • 1. From waterfall plots to spaghetti plots in early oncology clinical development.
    Mercier F; Consalvo N; Frey N; Phipps A; Ribba B
    Pharm Stat; 2019 Oct; 18(5):526-532. PubMed ID: 30942559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals.
    Kim MS; Prasad V
    JAMA Netw Open; 2019 May; 2(5):e193981. PubMed ID: 31099871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use and misuse of waterfall plots.
    Shao T; Wang L; Templeton AJ; Jang R; Vera-Badillo FW; McNamara MG; Margolis M; Kim TK; Sinaei M; Shoushtari H; Tannock IF
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25359866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D waterfall plots: a better graphical representation of tumor response in oncology.
    Castanon Alvarez E; Aspeslagh S; Soria JC
    Ann Oncol; 2017 Mar; 28(3):454-456. PubMed ID: 27993798
    [No Abstract]   [Full Text] [Related]  

  • 5. Statistical Interpretation and Comparison of Waterfall Plots.
    Huang M; Chen C; Sun LZ
    JCO Clin Cancer Inform; 2023 Sep; 7():e2300132. PubMed ID: 37906725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data augmentation based on waterfall plots to increase value of response data generated by small single arm Phase II trials.
    Han G; Pusztai L; Hatzis C
    Contemp Clin Trials; 2021 Nov; 110():106589. PubMed ID: 34634476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The design, analysis and application of mouse clinical trials in oncology drug development.
    Guo S; Jiang X; Mao B; Li QX
    BMC Cancer; 2019 Jul; 19(1):718. PubMed ID: 31331301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graphical Presentation of Patient-Treatment Interaction Elucidated by Continuous Biomarkers. Current Practice and Scope for Improvement.
    Shen YM; Le LD; Wilson R; Mansmann U
    Methods Inf Med; 2017 Jan; 56(1):13-27. PubMed ID: 27782287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Joint modeling tumor burden and time to event data in oncology trials.
    Shen Y; Anderson A; Sinha R; Li Y
    Pharm Stat; 2014; 13(5):286-93. PubMed ID: 25044957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graphical approaches to the analysis of safety data from clinical trials.
    Amit O; Heiberger RM; Lane PW
    Pharm Stat; 2008; 7(1):20-35. PubMed ID: 17323410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critical review of graphics for subgroup analyses in clinical trials.
    Ballarini NM; Chiu YD; König F; Posch M; Jaki T
    Pharm Stat; 2020 Sep; 19(5):541-560. PubMed ID: 32216035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of central and local serial CT assessments of metastatic renal cell carcinoma patients in a clinical phase IIB study.
    Felsch M; Zaim S; Dicken V; Lehmacher W; Scheuring UJ
    Acta Radiol; 2017 Feb; 58(2):249-255. PubMed ID: 27083205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A statistical simulation study finds discordance between WHO criteria and RECIST guideline.
    Mazumdar M; Smith A; Schwartz LH
    J Clin Epidemiol; 2004 Apr; 57(4):358-65. PubMed ID: 15135836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical plots in oncologic imaging, a primer for neuroradiologists.
    Bagheri S; Taghvaei M; Familiar A; Haldar D; Zandifar A; Khalili N; Vossough A; Nabavizadeh A
    Neuroradiol J; 2023 Aug; ():19714009231193158. PubMed ID: 37529843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutically-induced stable disease in oncology early clinical trials.
    Mercier F; Meneses-Lorente G; Grimsey P; Phipps A; Michielin F
    PLoS One; 2020; 15(5):e0233882. PubMed ID: 32470048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancing cancer drug development through precision medicine and innovative designs.
    Zhang W; Wang J; Menon S
    J Biopharm Stat; 2018; 28(2):229-244. PubMed ID: 29173004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyzing Therapeutic Change Using Modified Brinley Plots: History, Construction, and Interpretation.
    Blampied NM
    Behav Ther; 2017 Jan; 48(1):115-127. PubMed ID: 28077215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New guidelines to evaluate the response to treatment "RECIST"].
    Sasaki T
    Gan To Kagaku Ryoho; 2000 Dec; 27(14):2179-84. PubMed ID: 11142160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Independent action models and prediction of combination treatment effects for response rate, duration of response and tumor size change in oncology drug development.
    Sun LZ; Wu C; Li X; Chen C; Schmidt EV
    Contemp Clin Trials; 2021 Jul; 106():106434. PubMed ID: 34004341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample size allocation in multiregional equivalence studies.
    Liao JJZ; Yu Z; Li Y
    Pharm Stat; 2018 Sep; 17(5):570-577. PubMed ID: 29911346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.